Cantor Fitzgerald Increases Earnings Estimates for Prothena

Key Points

• Cantor Fitzgerald has significantly upgraded its earnings forecast for Prothena Corporation's FY2026 from **($3.66)** to **($0.25)** per share, while maintaining a **"Neutral"** rating on the stock.
• Prothena's current consensus estimate for full-year earnings stands at **($4.04)** per share, indicating a challenging financial outlook based on recent earnings performance.
• The company's stock is currently priced at **$7.64**, with a market capitalization of approximately **$410.99 million**, and has seen a notable fluctuation between a one-year low of **$4.32** and a high of **$23.66**.

Prothena Corporation plc (NASDAQ:PRTA - Free Report) - Equities researchers at Cantor Fitzgerald lifted their FY2026 earnings per share estimates for shares of Prothena in a report released on Tuesday, August 5th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the biotechnology company will post earnings of ($0.25) per share for the year, up from their previous forecast of ($3.66). Cantor Fitzgerald currently has a "Neutral" rating on the stock. The consensus estimate for Prothena's current full-year earnings is ($4.04) per share.

Other research analysts also recently issued research reports about the stock. Bank of America restated an "underperform" rating on shares of Prothena in a research report on Wednesday, May 28th. Jefferies Financial Group cut Prothena from a "buy" rating to a "hold" rating and set a $6.00 target price on the stock. in a research report on Tuesday, May 27th. Piper Sandler dropped their price objective on shares of Prothena from $110.00 to $81.00 and set an "overweight" rating on the stock in a report on Tuesday, May 27th. JMP Securities decreased their price target on shares of Prothena from $78.00 to $29.00 and set a "market outperform" rating on the stock in a research report on Tuesday, May 27th. Finally, Oppenheimer lowered Prothena from an "outperform" rating to a "market perform" rating in a research note on Tuesday, May 27th. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $30.25.

Prothena Stock Performance

NASDAQ PRTA opened at $7.64 on Thursday. The company has a market capitalization of $410.99 million, a price-to-earnings ratio of -1.35 and a beta of -0.03. The stock has a 50-day moving average of $6.07 and a 200 day moving average of $9.76. Prothena has a one year low of $4.32 and a one year high of $23.66.

Prothena (NASDAQ:PRTA - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The biotechnology company reported ($1.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.75). Prothena had a negative net margin of 2,929.30% and a negative return on equity of 62.17%. The business had revenue of $4.42 million during the quarter, compared to the consensus estimate of $5.36 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Deutsche Bank AG raised its holdings in Prothena by 195.7% during the 4th quarter. Deutsche Bank AG now owns 95,970 shares of the biotechnology company's stock valued at $1,329,000 after buying an additional 63,512 shares during the period. Barclays PLC increased its stake in shares of Prothena by 10.6% during the fourth quarter. Barclays PLC now owns 105,338 shares of the biotechnology company's stock valued at $1,458,000 after buying an additional 10,116 shares during the period. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Prothena in the 1st quarter worth approximately $126,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Prothena in the 4th quarter valued at $1,117,000. Finally, SG Americas Securities LLC lifted its position in Prothena by 92.9% during the first quarter. SG Americas Securities LLC now owns 72,559 shares of the biotechnology company's stock valued at $898,000 after acquiring an additional 34,947 shares during the last quarter. Institutional investors own 97.08% of the company's stock.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.